What is ARMP's current stock price?

ARMP (Armata Pharmaceuticals, Inc.) is currently trading at $5.17 with a market cap of $189.8M.

What sector is Armata Pharmaceuticals, Inc. in?

Armata Pharmaceuticals, Inc. (ARMP) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

ARMP Armata Pharmaceuticals, Inc.

AMEXHealthcare

$5.17+1.37%ClosedMarket Cap: $189.8M

As of 2026-08-24 16:00

Why ARMP matters now

Armata Pharmaceuticals, Inc. (ARMP) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.17 with +1.37% on the session and $189.8M in market capitalization.

The latest indexable market news headline is "Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update" from PRNewsWire.

Latest News

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate UpdatePRNewsWire · 2026-08-12

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?Zacks Investment Research · 2026-07-21

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02PRNewsWire · 2026-07-20

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus BacteremiaPRNewsWire · 2026-07-13

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02PRNewsWire · 2026-06-23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

AMEX

Beta

1.33

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.